« Back to Record
Citation APA

Ogbogu, P. U., Roufosse, F., Akuthota, P., Kuna, P., Groh, M., Reiter, A., Yokota, A., Siddiqui, S., Mutsaers, P. P., Li, B., Khoury, P., Bahadori, L. L., Bednarczyk, A., Bouma, G., Brooks, L., Ferreira, J., Grindebacke, H., Ho, C. C., Jain, P., Palmer, R. R., Jison, M., & Klion, A. (2026). Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. Nature medicine, 32(6), 2319. doi:10.1038/s41591-026-04315-8


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/409000

Ogbogu, P. U., Roufosse, F., Akuthota, P., Kuna, P., Groh, M., Reiter, A., Yokota, A., Siddiqui, S., Mutsaers, P. P., Li, B., Khoury, P., Bahadori, L. L., Bednarczyk, A., Bouma, G., Brooks, L., Ferreira, J., Grindebacke, H., Ho, C. C., Jain, P., Palmer, R. R., Jison, M., & Klion, A. (2026). Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. Nature medicine, 32(6), 2319. doi:10.1038/s41591-026-04315-8